The estimated Net Worth of Jeffrey Stein is at least $1.77 Milion dollars as of 7 June 2024. Jeffrey Stein owns over 8,000 units of Cidara Therapeutics Inc stock worth over $285,620 and over the last 10 years he sold CDTX stock worth over $37,398. In addition, he makes $1,451,970 as President, Chief Executive Officer a Director at Cidara Therapeutics Inc.
Jeffrey has made over 18 trades of the Cidara Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 8,000 units of CDTX stock worth $105,680 on 7 June 2024.
The largest trade he's ever made was buying 212,766 units of Cidara Therapeutics Inc stock on 23 May 2018 worth over $1,000,000. On average, Jeffrey trades about 12,140 units every 67 days since 2015. As of 7 June 2024 he still owns at least 24,580 units of Cidara Therapeutics Inc stock.
You can see the complete history of Jeffrey Stein stock trades at the bottom of the page.
Dr. Jeffrey L. Stein Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Stein also currently serves as a member of the executive committee of the Antimicrobial Working Group, a 501(c)(6) organization comprised of antimicrobial development companies, focused on the regulatory, investment and commercial environment for antimicrobial drug and diagnostic device development. Previously, Dr. Stein was the President and Chief Executive Officer of Trius Therapeutics, Inc., a publicly-traded pharmaceutical company, until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Prior to Trius, Dr. Stein was a venture partner and Kauffman Fellow at Sofinnova Ventures, a biotech venture capital fund. From 1999 until its acquisition by Pfizer Pharmaceuticals, Inc. in 2005, Dr. Stein was co-founder and Chief Scientific Officer at Quorex Pharmaceuticals, Inc., a private pharmaceutical company. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein currently serves on the board of directors of Ideaya Biosciences, Inc., a public biopharmaceutical company, and Paratek Pharmaceuticals Inc., a publicly-traded biopharmaceutical company. Dr. Stein holds a B.S. in marine biology and an M.S. in biology from California State University-Long Beach and a Ph.D. in marine biology from the University of California, San Diego. Dr. Stein conducted his postdoctoral research in bacterial genetics as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology.
As the President, Chief Executive Officer a Director of Cidara Therapeutics Inc, the total compensation of Jeffrey Stein at Cidara Therapeutics Inc is $1,451,970. There are no executives at Cidara Therapeutics Inc getting paid more.
Jeffrey Stein is 65, he's been the President, Chief Executive Officer a Director of Cidara Therapeutics Inc since 2018. There are 4 older and 13 younger executives at Cidara Therapeutics Inc. The oldest executive at Cidara Therapeutics Inc is Dr. Kenneth F. Bartizal Ph.D., 70, who is the Chief Devel. Officer.
Jeffrey's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, STE 101, , SAN DIEGO, CA, 92121.
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio... a Steve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include: